Supernus Pharmaceuticals Analyst Ratings
Supernus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 65.67% | Piper Sandler | $42 → $43 | Maintains | Overweight |
| 10/25/2023 | 61.82% | Piper Sandler | $43 → $42 | Maintains | Overweight |
| 05/10/2023 | 77.23% | Piper Sandler | $45 → $46 | Maintains | Overweight |
| 01/23/2023 | 81.08% | Piper Sandler | $40 → $47 | Maintains | Overweight |
| 08/31/2022 | 46.41% | Piper Sandler | $33 → $38 | Maintains | Overweight |
| 04/13/2021 | 54.11% | Jefferies | $25 → $40 | Upgrades | Hold → Buy |
| 06/16/2020 | 19.44% | Piper Sandler | $25 → $31 | Upgrades | Neutral → Overweight |
| 06/15/2020 | -7.53% | Jefferies | → $24 | Reinstates | → Hold |
| 04/16/2020 | -7.53% | Stifel | $25 → $24 | Maintains | Hold |
| 11/07/2019 | -11.39% | Stifel | $55 → $23 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/17/2018 | 142.73% | Mizuho | $61 → $63 | Maintains | Buy |
| 11/12/2018 | 150.43% | B. Riley Securities | $68 → $65 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2023 | 65.67% | 派珀·桑德勒 | 42 美元 → 43 美元 | 維護 | 超重 |
| 2023 年 10 月 25 日 | 61.82% | 派珀·桑德勒 | 43 美元 → 42 美元 | 維護 | 超重 |
| 05/10/2023 | 77.23% | 派珀·桑德勒 | 45 美元 → 46 美元 | 維護 | 超重 |
| 2023 年 1 月 23 日 | 81.08% | 派珀·桑德勒 | 40 美元 → 47 美元 | 維護 | 超重 |
| 08/31/2022 | 46.41% | 派珀·桑德勒 | 33 美元 → 38 美元 | 維護 | 超重 |
| 04/13/2021 | 54.11% | 傑富瑞集團 | 25 美元 → 40 美元 | 升級 | 持有 → 買入 |
| 06/16/2020 | 19.44% | 派珀·桑德勒 | 25 美元 → 31 美元 | 升級 | 中性 → 超重 |
| 06/15/2020 | -7.53% | 傑富瑞集團 | → 24 美元 | 恢復 | → 按住 |
| 2020 年 4 月 16 日 | -7.53% | Stifel | 25 美元 → 24 美元 | 維護 | 保持 |
| 11/07/2019 | -11.39% | Stifel | 55 美元 → 23 美元 | 降級 | 買入 → 持有 |
| 2019 年 6 月 11 日 | — | 傑富瑞集團 | 降級 | 買入 → 持有 | |
| 12/17/2018 | 142.73% | 瑞穗市 | 61 美元 → 63 美元 | 維護 | 買 |
| 11/12/2018 | 150.43% | B. 萊利證券 | 68 美元 → 65 美元 | 維護 | 買 |
What is the target price for Supernus Pharmaceuticals (SUPN)?
Supernus Pharmicals（SUPN）的目標價格是多少？
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on November 9, 2023. The analyst firm set a price target for $43.00 expecting SUPN to rise to within 12 months (a possible 65.67% upside). 4 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年11月9日公佈了Supernus Pharmicals（納斯達克股票代碼：SUPN）的最新目標股價。該分析公司將目標股價定爲43.00美元，預計SUPN將在12個月內升至12個月內（可能上漲65.67％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?
Supernus Pharmicals（SUPN）的最新分析師評級是多少？
The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.
派珀·桑德勒對Supernus Pharmicals（納斯達克股票代碼：SUPN）的最新分析師評級由派珀·桑德勒提供，Supernus Pharmicals維持增持評級。
When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?
Supernus Pharmicals（SUPN）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Supernus Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Supernus Pharmicals的最新評級是在2023年11月9日公佈的，因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?
分析師對Supernus Pharmicals（SUPN）的評級正確嗎？
While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $42.00 to $43.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $25.96, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但Supernus Pharmicals（SUPN）的最新評級維持不變，目標股價爲42.00美元至43.00美元。Supernus Pharmicals（SUPN）目前的交易價格爲25.96美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。